Orforglipron, an oral GLP-1, showed significant weight loss in Phase III trials, comparable to injectable GLP-1s, supporting its potential in obesity treatment. Lilly aims to include orforglipron in ...
Editor's note: This article has been updated to provide clarity on a head-to-head study Eli Lilly conducted on its candidate, orforglipron. A pill version under development of Novo Nordisk's (NVO) GLP ...
(Reuters) -Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's new national priority voucher, suggesting it is a strong candidate ...
MeiraGTx Holdings plc (NASDAQ:MGTX) stock is trading higher after the company inked a strategic collaboration in the area of ophthalmology with Eli Lilly and Co. (NYSE:LLY). MeiraGTx will grant Lilly ...
EXCLUSIVE: Tribeca Studios has partnered with the pharmaceutical company Lilly to launch Vital Stories, a new creative initiative designed to empower filmmakers to tell authentic, inclusive, and ...
The FDA has released the second batch of recipients for the new "national priority voucher" program, with executives for two of the beneficiaries appearing in the Oval Office with President Donald ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback